ADDIN EN.CITE (34)Clinical trials are needed to determine if current and emerging treatments targeting endothelin-1, nitric oxide synthesis, prostacyclin, serotonin, and peroxisome proliferator-activated receptor g can improve outcomes for select patients with CKD-associated pulmonary hypertension. The gene discussed is EDN1; the disease is chronic kidney disease.